Bruker Corp. (NSDQ:BRKR) said today it inked a deal to pick up Oncovision‘s preclinical imaging business for an undisclosed amount.
Oncovision will retain its clinical human imaging business, including its Mammi PET breast cancer diagnostic tool, the companies said.
“With this planned acquisition, Bruker expects to strengthen its expertise and leadership in preclinical imaging. The unique, performance-leading SiPM PET technology and products developed by Oncovision in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full field of view, increasing the high-resolution FOV by an order of magnitude compared to traditional PET systems, thereby facilitating quantitative imaging investigations. This unique and proprietary PET technology is one of the most important imaging modalities for translational research imaging. Our successful collaboration with Oncovision has led to the recent introduction of the performance-leading Albira Si PET/SPECT/CT system, and it now has also resulted in the first PET insert for high-field MRI systems for simultaneous PET and MRI measurements,” preclinical imaging division prez Dr. Wulf Jung said in a press release.
Bruker said it has partnered with Oncovision for years to market the Albira systems, to develop a new Albira Si system through other collaborations, including a 3 Tesla SiPM-PET/MRI system.
“Bruker is the undisputed leader in preclinical imaging with a unique portfolio of imaging modalities. Our preclinical team is delighted to join a company so well known for their innovation and dedication to excellence. The combined resources will accelerate the development and integration of our molecular imaging technologies, and fulfill the growing demand from translational scientists,” Oncovision CEO Ignasi Vivas said in prepared remarks.
